Unique initiative embedding patient-centric clinical research within PSR’s core services in orphan diseases. Hoofddorp, the Netherlands, November 08, 2016 / B3C newswire / -- PSR Orphan Experts, a specialty orphan drug consulting and clinical research …
Melbourne, Australia, and Utrecht, the Netherlands, November 08, 2016 / B3C newswire / -- AdAlta Limited (ASX: 1AD), a biotechnology company specialising in the discovery and development of protein-based therapeutics, and Crossbeta Biosciences, a …
Agendia signs partnership agreement with Cryogene and Mist for Middle East distribution Irvine, CA, USA and Amsterdam, the Netherlands, November 08, 2016 / B3C newswire / -- Agendia, Inc., a world leader in personalized medicine and molecular cancer …
Cologne, Germany, November 07, 2016 / B3C newswire / -- The supervisory board of AYOXXA Biosystems GmbH announces that Mr. Rodney Turner has assumed duties as the interim CEO of AYOXXA effective October 15, 2016. Mr. Turner is pleased to lead the company …
Melbourne, Australia and Freising, Germany, November 07, 2016 / B3C newswire / -- AdAlta Ltd (ASX: 1AD), the biotechnology company advancing its lead i-body candidate towards clinical development, and XL-protein GmbH, a privately owned German …
Respiratory Syncytial Virus (RSV), a common contagious lung infection, is a global health threat responsible for up to 200,000 deaths worldwide annually UK Phase I trial supported with EUR 3.44 m from Wellcome Trust, taking place at Imperial College, …
Tübingen, Germany, November 04, 2016 / B3C newswire / -- Atriva Therapeutics GmbH announces that the USPTO issued the Notice of allowance meaning that grant of one of its core patents: “MEK Inhibitors in the treatment of virus diseases” (US Application 14/ …
Langenfeld, Germany / Tehran, Iran, November 04, 2016 / B3C newswire / -- ARTES Biotechnology and BioSun Pharmed announced to join forces for the development and manufacturing of a HPV (human papilloma virus) vaccine in Iran. The agreed long-term …
Top-line results from both the ongoing Phase III clinical study for acute gastroenteritis and gastritis and the ongoing Phase II clinical study for diarrhea-predominant irritable bowel syndrome (IBS-D) are expected in mid-2017 Over two-thirds of the …
Basel, Switzerland, November 03, 2016 / B3C newswire / -- NBE Therapeutics AG, a biopharmaceutical company developing next-generation antibody-drug conjugates (ADCs) for improved cancer therapy, today announced closing of a CHF 20 million Series B …
Tel-Aviv, Israel, November 2, 2016 / B3C newswire / --RedHill Biopharma Ltd. (NASDAQ/TASE: RDHL) (“RedHill” or the “Company”), a biopharmaceutical company primarily focused on the development and commercialization of late clinical-stage, proprietary, …
The company also announces new patient awareness platform to help aid in breast cancer treatment decisions Irvine, CA, USA and Amsterdam, the Netherlands, November 1, 2016 / B3C newswire / -- Agendia, Inc., a world leader in personalized medicine and …
Self-testing is increasingly recognized for its potential to revolutionize HIV diagnosis and reach at-risk individuals who do not know their HIV status. This has the potential to improve detection rates in key populations. Self-testing is seen as a …
The “BRIDGE” initiative offers German patients free access to Agendia’s MammaPrint® breast cancer recurrence assay Data from the MINDACT trial shows Mammaprint is the only test on the German market supported by the highest level of medical evidence (1A) …
The Technical Directors will support BioPharmaSpec’s growing structural and physicochemical characterization business Jersey, UK and Malvern, PA. USA, October 25, 2016 / B3C newswire / -- BioPharmaSpec, a leading contract research organization (CRO) …
Basel, Switzerland and Prague, Czech Republic, October 20, 2016 / B3C newswire / -- NBE Therapeutics AG and SOTIO a.s. today announced that the companies have entered into a collaboration for the development of next-generation antibody-drug conjugates ( …
Amsterdam, the Netherlands, October 20, 2016 / B3C newswire / --Synaffix BV announced today it has entered into a Commercial License Agreement with ADC Therapeutics for its proprietary GlycoConnect™ and HydraSpace™ site-specific antibody-drug conjugate …
RedHill has received from the Japan Patent Office a Notice of Allowance for a new patent covering RHB-104 for multiple sclerosis (MS), expected to be valid until 2032, once granted RedHill’s robust RHB-104 patent portfolio covering its oral antibiotic …
Irvine, CA, USA and Amsterdam, the Netherlands, October 17, 2016 / B3C newswire / -- Agendia, Inc., a world leader in personalized medicine and molecular cancer diagnostics, announced today the appointment of three new members to its Medical Advisory Board …
Vienna, Austria, October 17, 2016 / B3C newswire / -- Hookipa Biotech AG, a biotech company pioneering a new class of immunotherapeutics and vaccines based on its proprietary arenavirus vector platforms, today announces the award of a fifth major grant …
